San Francisco-based Rigel Pharmaceuticals on Thursday announced it will acquire the U.S. rights to Blueprint Medicines’ FDA-approved non-small cell lung cancer drug Gavreto (pralsetinib).
Tag Archive for: nonsmall cell lung cancer (NSCLC)
Bristol Myers Squibb on Sunday announced that it has entered into a definitive merger agreement with cancer-focused biotech Mirati Therapeutics in a bid to grow its oncology franchise.
Japan’s Takeda Pharmaceutical said on Monday it will voluntarily withdraw its lung cancer therapy from the United States, where it had received an accelerated approval in 2021, after it failed to meet the main goal in a late-stage study.
Spectrum Pharmaceuticals Inc. said on Friday the U.S. Food and Drug Administration (FDA) declined to approve its experimental lung cancer drug due to inadequate data, prompting the drugmaker to cut jobs.
Development-stage biotech company Omega Therapeutics announced Thursday that its Investigational New Drug (IND) application for its hepatocellular carcinoma (HCC) candidate, OTX-2002, has received clearance from the U.S. Food and Drug Administration.
Regeneron Pharmaceuticals Inc. said on Thursday the company would buy the global rights to the cancer drug Libtayo from French drugmaker Sanofi SA in a deal that includes an upfront payment of $900 million.
